Designed for HCPs, this resource summarises the new updated ICR recommendations, detailing how the diagnosis and management of ITP has evolved as new evidence has become available.1
KEY AREAS COVERED:
- Therapy goals
- Strength of supporting data for current medical treatments
- Personalising treatment plans
- TPO-RAs for subsequent ITP therapy
REVOLADE is indicated for the treatment of patients aged 1 year and above with primary ITP lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).2
REVOLADE is indicated in adult patients with chronic HCV infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.2
REVOLADE is indicated in adult patients with acquired SAA who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.2
Abbreviations: HCP, healthcare professional; HCV, hepatitis C virus; ICR, International Consensus Report; ITP, immune thrombocytopenia; SAA, severe aplastic anaemia; TPO-RA, thrombopoietin-receptor agonist.
- Provan D, et al. Blood Adv. 2019;3:3780–3817.
- REVOLADE Summary of Product Characteristics.